Showing results (1-10 of 159) with videos related to
Sort By:
Pageof 16
Current Opinion in Lipidology|December 15, 2021
Therapeutic application of genome editing in dyslipidemiaMadelynn N Whittaker, Kiran MusunuruScience (New York, N.Y.)|June 27, 2024
An epigenetic editor to silence genesMadelynn N Whittaker, Kiran MusunuruAmerican Journal of Human Genetics|November 4, 2023
Efficient in vivo prime editing corrects the most frequent phenylketonuria variant, associated with high unmet medical needDominique L Brooks, Madelynn N Whittaker, Ping Qu, et al.HGG Advances|November 3, 2023
A base editing strategy using mRNA-LNPs for in vivo correction of the most frequent phenylketonuria variantDominique L Brooks, Madelynn N Whittaker, Hooda Said, et al.Biorxiv : the Preprint Server for Biology|June 9, 2023
Epigenome Editing Durability Varies Widely Across Cardiovascular Disease Target GenesMadelynn N Whittaker, Lauren C Testa, Aidan Quigley, et al.Annual Review of Medicine|November 25, 2020
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 InhibitionKiran MusunuruAdvances in Experimental Medicine and Biology|December 1, 2022
An Overview of Genome Editing in Cardiovascular and Metabolic DiseasesKiran MusunuruLipids|June 5, 2010
Atherogenic dyslipidemia: cardiovascular risk and dietary interventionKiran MusunuruJournal of the American College of Cardiology|December 2, 2017
Genome Editing: The Recent History and Perspective in Cardiovascular DiseasesKiran MusunuruPageof 16